logo
Plus   Neg
Share
Email

Ariad Stops Phase 3 Epic Trial Of Iclusig In Patients With Newly Diagnosed CML

Ariad Pharmaceuticals Inc. (ARIA) announced Friday that it is discontinuing the Phase 3 EPIC or Evaluation of Ponatinib versus Imatinib in Chronic Myeloid Leukemia trial of Iclusig (ponatinib) in patients with newly diagnosed chronic myeloid leukemia. The company said the decision was made in the interest of patient safety based on a recent assessment of data in the clinical trial.

Ariad and the U.S. Food and Drug Administration mutually agreed that the trial should be terminated because arterial thrombotic events were observed in patients treated with Iclusig.

"Our decision to stop the EPIC trial at this time is based on our current evaluation of the safety data in the trial since it was placed on partial clinical hold last week,"stated Timothy Clackson, president of research and development and chief scientific officer at ARIAD.

The company noted that patients in the EPIC trial are being removed from treatment and will be transferred to the care of their physician.

The company announced in early September that fifty percent of patients, or approximately 264 patients, had been enrolled in the EPIC trial by that time. Final enrollment is 307 patients.

Iclusig is commercially available in the U.S. and EU for patients with resistant or intolerant CML and Philadelphia-chromosome positive acute lymphoblastic leukemia.

The company stated that it continues to work with health authorities to make appropriate changes to the Iclusig product labeling to reflect the recently announced safety findings from the pivotal PACE trial that was the basis of its marketing approvals.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
SCARPA North America has recalled about 4,200 ski boots due to risk of fall. The company has recalled Maestrale RS and Maestrale Men's ski boots as its shell can crack, posing a fall hazard and risk of injury to the consumer. The recall involves the Fall 2017 Maestrale RS and Maestrale Men's Ski... Walt Disney's (DIS) Frozen 2, the sequel to its 2013 blockbuster, is expected to record a strong domestic opening of over $100 million this weekend. Frozen 2 will become the 10th animated film to debut with over $100 million and the first animated film outside the summer window to hit the mark. Frozen... Indonesia is exploring a total ban on the use of electronic cigarettes and vape products in the country due to healthcare concerns following the lung illness outbreak related to vaping in the U.S., according to reports. However, the South-East Asian country has not reported any cases of vaping-related illness. Chain-smoking Indonesia is the world's second largest tobacco market.
Follow RTT
>